Lactic Acid Bacteria Composition for Recurrent Cystitis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections and related inflammations of the urinary tract and bladder, particularly recurrent cystitis caused by Escherichia coli, are ineffective in providing long-term protection and are often associated with side effects, as they fail to address the adhesion of pathogens to epithelial cells and do not offer a natural, sustained barrier against infections.
Innovation Solution
A composition comprising specific strains of lactic bacteria with antibacterial and anti-inflammatory properties, such as Lactobacillus plantarum and Lactobacillus paracasei, combined with cranberry extract and D-mannose, which inhibit E. coli adhesion and proliferation, and oxalate-degrading bacteria to provide a long-lasting preventive and curative treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cystitis are used, then bacterial infections are temporarily suppressed, but long-term protection is not achieved and side effects occur
Solution Approach 1:
The composition enables the patient's own flora to fight infections by stimulating the production of natural protective substances (sIgA, IL-4, IL-10) and restoring beneficial bacteria, allowing the body to defend itself against E. coli without continuous external intervention or harmful antibiotics
Solution Approach 2:
The composition is administered before infections occur to restore and maintain a protective flora balance, preventing E. coli adhesion and proliferation through预先建立的免疫屏障 and beneficial bacteria competition, rather than treating infections after they establish
2Productivity
If antibiotics are used to treat E. coli infections, then bacterial proliferation is reduced, but the adhesion mechanism to epithelial cells is not addressed and recurrence occurs
Solution Approach 1:
The composition applies preliminary anti-action by stimulating the production of secretory IgA and beneficial bacteria that prevent E. coli adhesion to epithelial cells before infection can establish, blocking the initial attachment step that antibiotics cannot prevent
Solution Approach 2:
The composition introduces intermediary substances including sIgA, IL-4, IL-10, and beneficial bacteria that mediate between the host immune system and E. coli, providing sustained protection through biological mechanisms rather than direct bacterial killing
3Object-generated harmful factors
If a natural barrier approach is used, then side effects are minimized, but the effectiveness against recurrent infections is insufficient without addressing adhesion
Solution Approach 1:
The composition merges multiple protective mechanisms into one formulation: prebiotics to feed beneficial bacteria, probiotics to restore flora balance, and immunostimulants to enhance sIgA and cytokine production, creating a synergistic natural barrier that effectively prevents E. coli adhesion and recurrent infections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces E. coli adhesion and inflammation, offering a natural and sustained barrier against urinary tract infections, including recurrent cystitis, with minimal side effects and long-term protection by stimulating IL-4 and IL-10 production and degrading oxalates, thus preventing renal gravel formation.
Implementation Method 1
at least one strain of bacteria having both a specific antibacterial activity against E. coli
Implementation Method 2
an anti-inflammatory activity with stimulation of the Interleukin IL-4 and Interleukin IL-10 production
Implementation Method 3
at least one strain of bacteria having an oxalate-degrading activity
Implementation Method 4
which inhibit E. coli adhesion and proliferation
Data Source
AI summary
A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.